These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 16400836)

  • 1. The use of MRI as an outcome measure in clinical trials.
    Li DK; Li MJ; Traboulsee A; Zhao G; Riddehough A; Paty D
    Adv Neurol; 2006; 98():203-26. PubMed ID: 16400836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
    Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives.
    Bar-Zohar D; Agosta F; Goldstaub D; Filippi M
    Mult Scler; 2008 Jul; 14(6):719-27. PubMed ID: 18424478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of MRI in the diagnosis of multiple sclerosis.
    Traboulsee AL; Li DK
    Adv Neurol; 2006; 98():125-46. PubMed ID: 16400831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging in multiple sclerosis.
    Napoli SQ; Bakshi R
    Rev Neurol Dis; 2005; 2(3):109-16. PubMed ID: 16400309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of MRS and fMRI in multiple sclerosis.
    Tartaglia MC; Arnold DL
    Adv Neurol; 2006; 98():185-202. PubMed ID: 16400835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
    Krapf H; Morrissey SP; Zenker O; Zwingers T; Gonsette R; Hartung HP;
    Neurology; 2005 Sep; 65(5):690-5. PubMed ID: 16157900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs.
    Sormani MP; Bonzano L; Roccatagliata L; De Stefano N
    Mult Scler; 2011 May; 17(5):630-3. PubMed ID: 21177320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple sclerosis: use of MRI in evaluating new therapies.
    Miller DH
    Semin Neurol; 1998; 18(3):317-25. PubMed ID: 9817536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?
    Giacomini PS; Arnold DL; Bar-Or A; Antel JP
    Arch Neurol; 2009 Jan; 66(1):19-20. PubMed ID: 19139295
    [No Abstract]   [Full Text] [Related]  

  • 12. The incomplete nature of multiple sclerosis relapse resolution.
    Lublin FD
    J Neurol Sci; 2007 May; 256 Suppl 1():S14-8. PubMed ID: 17337274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance imaging of multiple sclerosis lesions. Measuring outcome in treatment trials.
    Simon JH
    West J Med; 1996 Jun; 164(6):502-9. PubMed ID: 8764625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?
    Goodin DS
    Ann Neurol; 2006 Apr; 59(4):597-605. PubMed ID: 16566022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of modern magnetic resonance techniques to monitor disease evolution in multiple sclerosis.
    Filippi M; Rocca MA
    Adv Neurol; 2006; 98():167-83. PubMed ID: 16400834
    [No Abstract]   [Full Text] [Related]  

  • 16. Seeing injectable MS therapies differently: they are more similar than different.
    Fox RJ; Arnold DL
    Neurology; 2009 Jun; 72(23):1972-3. PubMed ID: 19439722
    [No Abstract]   [Full Text] [Related]  

  • 17. Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients.
    Minneboo A; Uitdehaag BM; Ader HJ; Barkhof F; Polman CH; Castelijns JA
    Neurology; 2005 Jul; 65(1):56-61. PubMed ID: 16009885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI to monitor treatment efficacy in multiple sclerosis.
    Fazekas F; Soelberg-Sorensen P; Comi G; Filippi M
    J Neuroimaging; 2007 Apr; 17 Suppl 1():50S-55S. PubMed ID: 17425736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced magnetic resonance imaging metrics: implications for multiple sclerosis clinical trials.
    Zivadinov R
    Methods Find Exp Clin Pharmacol; 2009; 31(1):29-40. PubMed ID: 19357796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome measures in multiple sclerosis clinical trials.
    Andersson PB; Goodkin DE
    Baillieres Clin Neurol; 1997 Oct; 6(3):409-28. PubMed ID: 10101581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.